Endocrine Abstracts

The notable expression of the androgen receptor (AR) in breast cancer suggests an important biological role and, hence, a window of utilizing it as a therapeutic target. Due to the undesirable side effects of AR agonists, attempts have been undertaken to develop tissue-selective androgen receptor modulators (SARMs). One such SARM is Cl-4AS-1, which has previously been shown to behave similar to the natural AR agonist, dihydrotestosterone (DHT). We aimed to examine the effects ...